Webb Michael Reed
Known title: SVP & Chief HR OfficerCIK: 0001970916
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Transaction History
| SCSC | ▲ Buy | Grant | 5,614 | $0 | 9/1/2026 | View on chart |
| ROG | ▼ Sell | Open Market | 954 | $106K | 3/2/2026 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 351 | $38K | 2/28/2026 | View on chart |
| ROG | ▼ Sell | Open Market | 673 | $72K | 2/20/2026 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 307 | $34K | 2/19/2026 | View on chart |
| ROG | ▼ Sell | Open Market | 1,197 | $127K | 2/19/2026 | View on chart |
| ROG | ▲ Buy | Grant | 3,451 | $0 | 2/18/2026 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 197 | $11K | 4/11/2025 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 316 | $28K | 2/19/2025 | View on chart |
| ROG | ▲ Buy | Grant | 3,913 | $0 | 2/12/2025 | View on chart |
| ROG | ▼ Sell | Open Market | 416 | $45K | 11/8/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 314 | $36K | 4/11/2024 | View on chart |
| ROG | ▲ Buy | Grant | 2,940 | $0 | 2/19/2024 | View on chart |
| ROG | ▲ Buy | Grant | 2,190 | $0 | 4/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Barclays Raises ScanSource Price Target to $51
Barclays maintained an Equal-Weight rating on ScanSource while raising its price target to $51. The firm highlighted the company's position within the technology services sector, which continues to face industry-wide challenges. This update provides a specific valuation benchmark for investors, sitting below the current average analyst target of $64.50.
Barclays Raises ScanSource Price Target to $51. Barclays maintained an Equal-Weight rating on ScanSource while raising its price target to $51. The firm highlighted the company's position within the technology services sector, which continues to face industry-wide challenges. This update provides a specific valuation benchmark for investors, sitting below the current average analyst target of $64.50.